Compare Quest Diagnostics Inc (DGX) vs T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs T-Rex 2X Inverse MSTR Daily Target ETF — how do they compare? Quest Diagnostics Inc trades at $229.97 (market cap $25.48B), while T-Rex 2X Inverse MSTR Daily Target ETF trades at $2.61 (market cap $94.46M). The key difference: Quest Diagnostics Inc is far larger — about 269.7× T-Rex 2X Inverse MSTR Daily Target ETF's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while T-Rex 2X Inverse MSTR Daily Target ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and T-Rex 2X Inverse MSTR Daily Target ETF for 8 Days on average.
| DGX | MSTZ | |
|---|---|---|
Market Cap | $25.48B | $94.46M |
Volume | 941,866 | 104,717,733 |
Sector | Health | Leveraged / Inverse |
52-Week High | $247.45 | $27.92 |
52-Week Low | $173.49 | $2.29 |
Typical Hold Time | 56 Days | 8 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
MSTZ trades at $2.62, down 1.5% today, with technical indicators showing a bearish bias as moving averages signal selling pressure while oscillators remain neutral. The stock faces resistance at $3 with support at $2, indicating a tight trading range. Recent ETF coverage highlights its inclusion in leveraged fund discussions, though specific company fundamentals remain undisclosed in available data.
The outlook for MSTZ hinges on upcoming financial disclosures to clarify valuation metrics like P/E and profitability. Key risks include limited public financial data and market volatility. Investors await earnings reports to assess growth potential amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →
